Financial Statements
Financial Statements

Bayer Group Consolidated Statements of Cash Flows

    [Table 22]
 3rd
Quarter
2009
3rd
Quarter
2010
First Nine
Months
2009
First Nine
Months
2010
 € million€ million€ million€ million
Income after taxes2492851,2031,503
Income taxes1354549483
Non-operating result262267888772
Income taxes paid or accrued(131)(106)(696)(925)
Depreciation and amortization6806642,0562,097
Change in pension provisions(24)(225)(238)(459)
(Gains) losses on retirements of noncurrent assets1(10)(133)(35)
Gross cash flow1,1728793,6293,436
     
Decrease (increase) in inventories(48)(104)327(121)
Decrease (increase) in trade accounts receivable427505(371)(394)
(Decrease) increase in trade accounts payable112(168)(302)32
Changes in other working capital, other non-cash items(146)443326879
Net cash provided by (used in) operating activities (net cash flow)1,5171,5553,6093,832
     
Cash outflows for additions to property, plant, equipment and intangible assets(420)(395)(1,080)(990)
Cash inflows from sales of property, plant, equipment and other assets24154740
Cash inflows from (outflows for) divestitures6365777
Cash inflows from (outflows for) noncurrent financial assets32(209)116(452)
Cash outflows for acquisitions less acquired cash0(1)(2)(18)
Interest and dividends received42157448
Cash inflows from (outflows for) current financial assets6(100)(1)(83)
Net cash provided by (used in) investing activities(310)(639)(789)(1,378)
     
Capital contributions0000
Dividend payments and withholding tax on dividends0(1)(973)(1,159)
Issuances of debt972222,649713
Retirements of debt(346)(1,339)(3,224)(2,110)
Interest paid including interest rate swaps(259)(254)(1,078)(773)
Interest received from interest rate swaps7896361325
Cash outflows for the purchase of additional interests in subsidiaries(6)(5)(46)(6)
Net cash provided by (used in) financing activities(436)(1,281)(2,311)(3,010)
     
Change in cash and cash equivalents due to business activities771(365)509(556)
     
Cash and cash equivalents at beginning of period1,8342,5512,0942,725
     
Change in cash and cash equivalents due to changes in scope of consolidation0030
Change in cash and cash equivalents due to exchange rate movements(10)(62)(11)(45)
     
Cash and cash equivalents at end of period2,5952,1242,5952,124
2009 figures restated
http://www.stockholders-newsletter-q3-2010.bayer.com/en/cash-flows.aspx

Copyright © Bayer AG

Print Page

Search

Download Center

Publications

Services

Special Interest